Sotalol Hydrochloride Tablet
NDC Package 55154-8179-0

11-digit billing NDC: 55154817900

Package Information

Sotalol Hydrochloride tablets is sotalol hydrochloride/Sotalol hydrochloride (AF) tablets are contraindicated in patients with:•Sinus bradycardia, sick sinus syndrome, second and third degree AV block, unless a functioning pacemaker is present•Congenital or acquired long QT syndromes•Cardiogenic shock or decompensated heart failure•Serum potassium <4 mEq/L•Bronchial asthma or related bronchospastic conditions•Hypersensitivity to sotalolFor the treatment of AFIB/AFL, sotalol hydrochloride/sotalol hydrochloride AF tablets are also contraindicated in patients with:•Baseline QT interval >450 msec. This formulation utilizes a tablet delivery system. Marketed by Cardinal Health 107, Llc, this product is identified by NDC 55154-8179 and is authorized under FDA application ANDA076140.

Identification & Billing

NDC Package Code
55154-8179-0
Package Description
10 BLISTER PACK in 1 BAG / 1 TABLET in 1 BLISTER PACK
Product Code
11-Digit Billing Format
55154817900
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sotalol Hydrochloride
Non-Proprietary Name
Sotalol Hydrochloride
Substance Name
Sotalol Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Sotalol hydrochloride/Sotalol hydrochloride (AF) tablets are contraindicated in patients with:•Sinus bradycardia, sick sinus syndrome, second and third degree AV block, unless a functioning pacemaker is present•Congenital or acquired long QT syndromes•Cardiogenic shock or decompensated heart failure•Serum potassium <4 mEq/L•Bronchial asthma or related bronchospastic conditions•Hypersensitivity to sotalolFor the treatment of AFIB/AFL, sotalol hydrochloride/sotalol hydrochloride AF tablets are also contraindicated in patients with:•Baseline QT interval >450 msec

Regulatory & Marketing

Labeler Name
Cardinal Health 107, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA076140
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-11-2014
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55154-8179-0 identifies a specific commercial package of 10 blister pack in 1 bag / 1 tablet in 1 blister pack of Sotalol Hydrochloride, a human prescription drug labeled by Cardinal Health 107, Llc. This tablet is formulated for oral use and contains sotalol hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cardinal Health 107, Llc on March 11, 2014. The current certification is valid through December 31, 2027.

How is this Cardinal Health 107, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55154817900. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
55154-8179-0
11-Digit CMS (5-4-2)
55154-8179-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.